Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Current vaccines teach T cells to fight Omicron

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection - ScienceDirect

AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study

Jean-François Toussaint on LinkedIn: #covid19

Peptide Products for SARS-CoV-2

Vitamins, microelements and the immune system: current standpoint in the fight against coronavirus disease 2019, British Journal of Nutrition

JCI Insight - An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants

Statement on the antigen composition of COVID-19 vaccines